Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951004 | 0.72 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL27102080 | 0.69 | CA2 (0.39) | GABRA1GABRB2CA2TSHRTDP1 | |
| SCHEMBL10262040 | 0.69 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL25944335 | 0.68 | GABRA1 (0.34) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL5953571 | 0.65 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL16393553 | 0.65 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL15667084 | 0.64 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL5951184 | 0.64 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL16744224 | 0.64 | — | — | |
| SCHEMBL13019290 | 0.63 | GABRA1 (0.40) | GABRA1GABRG2GABRB3GABRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-9878995-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9790178-B2 | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20160297758-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160152609-A1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, NLRP1, PYCARD | GABRA1 4121/4885GABRG2 4279/4885GABRB3 3245/4885 |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | GABRA1 1992/4885GABRG2 1120/4885GABRB3 693/4885 |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | GABRA1 1992/4885GABRG2 1120/4885GABRB3 693/4885 |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | GABRA1 4038/4885GABRG2 4369/4885GABRB3 2841/4885 |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | GABRA1 3433/4885GABRG2 4495/4885GABRB3 4543/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | GABRA1 1992/4885GABRG2 1120/4885GABRB3 693/4885 |
| US-20160297758-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, UACA, TYMP | GABRA1 4118/4885GABRG2 3949/4885GABRB3 3880/4885 |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, CASP1, PYCARD | GABRA1 4005/4885GABRG2 4129/4885GABRB3 2690/4885 |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | GABRA1 3433/4885GABRG2 4495/4885GABRB3 4543/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | GABRA1 3433/4885GABRG2 4495/4885GABRB3 4543/4885 |
| US-20160152609-A1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | GABRA1 187/4885GABRG2 158/4885GABRB3 149/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | GABRA1 1992/4885GABRG2 1120/4885GABRB3 693/4885 |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | SLC1A2, B4GALT1, SLC6A1 | GABRA1 68/4885GABRG2 189/4885GABRB3 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.